Search
IDM-2
go.drugbank.com/drugs/DB05293ExperimentalIDM produces MAK cells from the patient's own white blood cells by activating these cells ex vivo to allow them to recognize and destroy tumor cells.
Magnesium salicylate
go.drugbank.com/drugs/DB01397ApprovedIt is available in several over-the-counter (OTC) formulations.
PSN357
go.drugbank.com/drugs/DB05044ExperimentalPSN357 is a glycogen phosphorylase inhibitor (GPI), which is designed to rapidly lower blood glucose levels by preventing glycogen breakdown to glucose in the liver.
Scorpion (centruroides) immune Fab2 antivenin (equine)
go.drugbank.com/drugs/DB13905ApprovedSevere scorpion stings may cause loss of muscle control and respiratory failure, warranting heavy sedation and hospitalization in an intensive care unit. … Envenomation by a scorpion sting can result in serious cardiovascular effects [A32483].
Ethotoin
go.drugbank.com/drugs/DB00754ApprovedEthotoin exerts an antiepileptic effect without causing general central nervous system depression. The mechanism of action is probably very similar to that of phenytoin.
Setiptiline
go.drugbank.com/drugs/DB09304ExperimentalIn Japan, the company Mochida started its commercialization for the treatment of depression started in 1989.
Meclofenamic acid
go.drugbank.com/drugs/DB00939ApprovedInvestigationalVet approvedA non-steroidal anti-inflammatory agent with antipyretic and antigranulation activities. It also inhibits prostaglandin biosynthesis.
Synonyms: N-(2,6-dichloro-m-tolyl)anthranilic acid, N-(2,6-dichloro-3-methylphenyl)anthranilic acidBardoxolone
go.drugbank.com/drugs/DB12651InvestigationalIn contrast, Bardoxolone in normal cells induces protective antioxidant/anti-inflammatory responses. … Bardoxolone has been used in trials studying the treatment of LYMPHOMA and Solid Tumors.
Lancovutide
go.drugbank.com/drugs/DB05029InvestigationalLancovutide, a peptide antibiotic, is in clinical development for the treatment of cystic fibrosis.
Drinabant
go.drugbank.com/drugs/DB05750InvestigationalAVE-1625 is an oral selective and potent antagonist of cannabinoid 1 (CB1) receptors having the same mechanism of action as rimonabant. … It is currently developed in obesity and its associated comorbidities. AVE-1625 is also being developed for the treatment of Alzheimer disease.